Format

Send to

Choose Destination
See comment in PubMed Commons below
Hepat Mon. 2014 Mar 9;14(3):e15076. doi: 10.5812/hepatmon.15076. eCollection 2014 Mar.

The IFN-λ Genetic Polymorphism Association With the Viral Clearance Induced by Hepatitis C Virus Treatment in Pakistani Patients.

Author information

1
Institute of Biochemistry and Biotechnology, University of the Punjab, Lahore, Pakistan ; Manchester Institute of Biotechnology, University of Manchester, Manchester, UK.
2
Manchester Institute of Biotechnology, University of Manchester, Manchester, UK ; Centre for Integrated Genomic Medical Research, University of Manchester, Manchester, UK.
3
Manchester Institute of Biotechnology, University of Manchester, Manchester, UK ; National University of Science and Technology, Islamabad, Pakistan.
4
Centre for Integrated Genomic Medical Research, University of Manchester, Manchester, UK.
5
Institute of Biochemistry and Biotechnology, University of the Punjab, Lahore, Pakistan.

Abstract

BACKGROUND:

Polymorphisms in the interferon λ (INF λ) genes on chromosome 19 have been associated with clearance of hepatitis C virus (HCV) induced by interferon and ribavirin therapy however there is no such data available for Pakistani patients with HCV infection.

OBJECTIVES:

In this study, the effects of single nucleotide polymorphisms (SNPs) have been investigated in response to treatment with interferon-α and ribavirin in a cohort of 75 HCV genotype 3a patients.

PATIENTS AND METHODS:

A total number of 50 SNPs from the Interferon λ region on chromosome 19 were genotyped to investigate allelic associations with the treatment response in HCV type 3a patients. Thirteen SNPs were associated with HCV clearance, with the most significant alleles being RS8109886 (Fisher's P = 0.0001), RS8113007 (Fisher's P = 0.0001) and RS12979860 (Fisher's P = 0.0002).

RESULTS:

These SNPs were found to be the most suitable SNPs for predicting treatment response in the present study. These findings support those reported previously. This could be used to improve HCV treatment strategies and suggest that Pakistani patients should be genotyped for the relevant SNPs to identify the patients who are more likely to respond to interferon and ribavirin therapy.

CONCLUSIONS:

This therapy is costly and can be accompanied by several adverse side-effects, hence pre-treatment prediction of patients who are most likely to benefit would have both economic and patient benefits in the long term.

KEYWORDS:

Antiviral Agents; Hepacivirus; Interferons; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Ribavirin

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Support Center